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resistant (1-3). Throughout Italy, the use of
macrolides, particularly the newest ones
(azithromycin and clarithromycin), has in-
creased in the treatment of infections caused by
Group A streptococci. This therapeutic approach
is contrary to current guidelines, which
recommend using betalactam antibiotics as first-
choice therapy and reserving macrolides only for
patients allergic to betalactams.
In 1997 in Finland, a decrease was observed
in the use of macrolide antibiotics in ambulatory
patients from 2.40 defined daily doses per 1,000
inhabitants in 1991 to 1.38 in 1992. Subse-
quently, the maintenance of doses at 1.28 to 1.74
defined daily doses resulted in a substantial
decrease in the percentage of group A
streptococcal resistance to erythromycin, re-
ported as 16.5% in 1992, 19% in 1993, 15.6% in
1994, 10% in 1995, and 8.6% in 1996 (4). These
data prompted us to evaluate such phenomena in
our geographic area, the urban area of Genoa,
Italy (approximately 120,000 inhabitants).
From January 1991 to June 1998, 311 (6.1%)
of 5,117 strains of S. pyogenes throat swabs from
patients with pharyngotonsillitis were isolated.
We observed a higher number of group A
streptococci isolates from throat swabs starting
in 1996 than we had in 1991 to 1995 (chi-square
= 35.653, p <0.0001). All isolates were tested for
susceptibility to penicillin and erythromycin by
standard susceptibility tests (broth microdilution)
as recommended by the National Committee for
Clinical Laboratory Standards. All isolates were
susceptible to penicillin. From 1991 to 1996, the
percentage of S. pyogenes resistant or with
intermediate resistance to erythromycin
increased from 0% to 50% (1992, 6%; 1993, 13%;
1994, 14%; 1995, 24%; 1996, 50%). In 1997 and
the first half of 1998, resistance to erythromycin
decreased to 39% and 34%, respectively. The
number of resistant strains before 1996 was
significantly lower than from 1996 to 1998 (chi-
square = 50.386, p <0.0001). Analysis of
antibiotic consumption in our district showed an
increase in the use of macrolides (erythromycin
and the new compounds clarithromycin and
azithromycin) from 0.445 defined daily dose per
1,000 inhabitants in 1994 to 1.140 in 1996. In
1997 and in the first half of 1998, consumption
decreased to 0.9 and 0.8, respectively; we
observed a correlation between the number of
resistant isolates and the defined daily dose
increase (correlation [R2] = 0.795, p = 0.0153).
S. pyogenes resistance to erythromycin rose
from 6% to 50% in only 4 years and then rapidly
decreased from 50% to 34% in an 18-month
period, corresponding to a 57% decrease in
defined daily dose (from 1.41 in 1996 to 0.8 in the
first half of 1998). Our data suggest that
S. pyogenes resistance to erythromycin is
associated with frequency of macrolide use.
Matteo Bassetti, Enrico Mantero, Giorgio Gatti,
Antonio Di Biagio, and Dante Bassetti
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Estimated Incidence of Clostridium
difficile Infection
To the Editor: Since the publication of our article
Increasing hospitalization and death, possibly
due to Clostridium difficile diarrheal disease (1),
we have received several requests to estimate
the incidence of C. difficile infection. Our
original study included only hospitalized
patients treated at the Lovelace Medical Center
from 1993 to 1996, and no information on the
incidence of C. difficile infection. In response to
these requests, we used inpatient and outpatient
medical claims for the Lovelace managed care
population to calculate incidence rates. We
searched medical claims for the Lovelace Health
Plan/Senior Plan (LHP) to identify patients who
had a C. difficile diagnosis between January 1,
1993, and December 31, 1997. LHP members are
residents of New Mexico, most residing in or near
Albuquerque.
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LHP had approximately 713,000 person-
years of enrollment from 1993 to 1997. We
identified 104 members with a C. difficile
diagnosis on a claims record during this period.
This group includes most of the patients in our
original study. Most patients (62.5%) were
identified exclusively from inpatient records;
another 15.4% had both an inpatient and an
outpatient record with a C. difficile diagnosis;
and 22.1% had only an outpatient C. difficile
diagnosis. We calculated an age-adjusted rate of
infection (adjusted to the 1990 U.S. population),
for each year and for the 5-year period. The
incidence of C. difficile infection for all members
during 1993 to 1997 was 14.8 cases per 100,000
person-years of enrollment. The patients rates
for male and female were essentially the same
(14.4 vs. 15.5, respectively). The rates increased
dramatically with age. For persons ages 0-4, the
age-adjusted rate per 100,000 person-years of
enrollment (number of cases) was 5.3 (2); for 5-14,
2.7 (3), for 15-24, 2.2 (2); for 24-34, 6.4 (6); for 35-44,
9.2 (12); for 45-54, 15.7 (17); 55-64, 16.8 (10); 65-74,
38.5 (19); and 75+, 98.9 (33). The overall average
rate of infection was 15.4; there were 104 cases.
The rate of infection may have declined since
1993 in this population. The 1993 rate was 24.5
per 100,000 person-years of enrollment, declin-
ing to 11.1 in 1997 (1993, 24.4; 1994, 19.1; 1995,
9.9; 1996, 12.3; and 1997, 11.1).
Our method for estimating rates has some
limitations. We did not examine laboratory
records to confirm the diagnosis. In addition,
some laboratory-confirmed infections may not
have resulted in a claims record with a C. difficile
diagnosis. The Lovelace managed-care popula-
tion is an insured, generally healthy population
that may not have the characteristics of patients
in other health care delivery settings or, because
of its geographic restriction, the characteristics
of the general U.S. population. Nevertheless,
these estimates provide a basis for determining
the magnitude of the public health problem of C.
difficile infection. Additional surveillance stud-
ies are needed to better estimate the incidence of
infection and to determine whether the
incidence has declined during recent years.
Floyd Frost,* Judith S. Hurley,*
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Diphtheria in Eastern Nepal
To the Editor: Diphtheria, caused by Corynebac-
terium diphtheriae, was a major childhood killer
until the advent of the Expanded Program on
Immunization when diphtheria, pertussis, and
tetanus (DPT) vaccination was greatly in-
creased; diphtheria gradually declined in many
countries. We report two cases of diphtheria
identified at the B.P. Koirala Institute of Health
Sciences Hospital, Dharan, Nepal.
During April 1996, a 6-year-old patient had
fever (for 5 days), difficulty in swallowing and
breathing, and change of voice (for 4 days).
Throat examination showed a grayish-white
membrane over the right tonsil, uvula, and
adjacent soft palate. The membrane could not be
removed, and the larynx could not be examined.
Swabs were taken from the membrane area and
sent to the laboratory, where smears were made
and stained by Gram and Albert stains. Gram-
stained smears showed a large number of gram-
positive bacilli with the appearance of Chinese
letters, and Albert stain showed bacilli with
numerous metachromatic granules. A diagnosis
of faucial diphtheria, with a strong possibility of
laryngeal diphtheria, was made. The patient was
treated with parenteral penicillin and diphtheria
antitoxin. His condition improved after 6 days of
therapy.
In December 1996, a 9-year-old patient
sought treatment for chronic pain and discharge
in the left ear. On examination, he had
mucopurulent discharge, antral perforation, and
mastoid tenderness. Throat examination showed
bilateral tonsilitis. A provisional diagnosis of
acute mastoiditis associated with acute septic
tonsillitis was made. Throat swabs were
collected and sent to the laboratory; smear
findings showed typical organisms morphologi-
cally resembling C. diphtheriae. Culture done on
10% defibrinated sheep blood agar and Loefflers
serum slope grew colonies consistent with
C. diphtheriae. In addition to local antibiotic to
the ear, the patient was given parenteral
penicillin, gentamicin, and metronidazole. Be-
cause the patient had no features of systemic
